AIM:NYSEAMERICAN
AIM ImmunoTech Inc
$0.16
0.00%
(0.00) 1D
$0.17
arrow_upward
+3.05% (+0.0049)bedtimeAfter hours
Closed: Nov 3, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AIM...
Open
$0.16
High
$0.16
Low
$0.16
Mkt. cap
6.44M
Avg. vol.
848.95K
Volume
159.83K
52-wk high
$2.10
52-wk low
$0.15
EPS
-$3.93
Beta
1.32
Shares outstanding
39.90M
No. of employees
20
Open
$0.16
High
$0.16
Low
$0.16
Mkt. cap
6.44M
Avg. vol.
848.95K
Volume
159.83K
52-wk high
$2.10
52-wk low
$0.15
EPS
-$3.93
Beta
1.32
Shares outstanding
39.90M
No. of employees
20
News stories
From web sources and news partners
Investing News Network
·
1 hour ago
Scully Royalty Receives Additional Trading Period From Nyse For Delayed Filing Of 2025 Form 20-F
TradingView
·
1 hour ago
NYSE Adds Four Transfer Agents to Planned Tokenized Securities Venue
Yahoo Finance
·
6 hours ago
As Meta Stock Suffers Its Worst Month in Years, S&P Delivers a Brutal $39 Billion Cash Flow Warning
Bloomberg.com
·
1 hour ago
Stock Futures Rise on AI Recovery as US Votes: Markets Wrap
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
HeadquartersPhiladelphia, Pennsylvania, United States
SectorBiotechnology
Industry-
Websiteaimimmuno.com